Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

References

• MurrayCJVosTLozanoRDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet20143849943582
   Web of Science ®Google Scholar
• KesslerRCBrometEJThe epidemiology of depression across culturesAnnu Rev Public Health201334111913823514317
   PubMed Web of Science ®Google Scholar
• KesslerRCBerglundPDemlerOThe epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)JAMA2003289233095310512813115
   PubMed Web of Science ®Google Scholar
• MurrayCJVosTLozanoRDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592197222323245608
   PubMed Web of Science ®Google Scholar
• MurrayCJLopezADAlternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease StudyLancet19973499064149815049167458
   PubMed Web of Science ®Google Scholar
• GelenbergAJFreemanMPMarkowitzJCPractice guideline for the treatment of patients with major depressive disorder third editionAm J Psychiatry201016710120068118
   PubMed Web of Science ®Google Scholar
• CleareAParianteCMYoungAHMembers of the Consensus MeetingEvidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelinesJ Psychopharmacol201529545952525969470
   PubMed Web of Science ®Google Scholar
• LamRWKennedySHGrigoriadisSCanadian Network for Mood and Anxiety Treatments (CANMAT)Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. PharmacotherapyJ Affect Disord2009117Suppl 1S26S4319674794
   PubMed Web of Science ®Google Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysisLancet2018391101281357136629477251
   PubMed Web of Science ®Google Scholar
• PapakostasGIThaseMEFavaMNelsonJCSheltonRCAre antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsBiol Psychiatry200762111217122717588546
   PubMed Web of Science ®Google Scholar
• CiprianiAKoestersMFurukawaTADuloxetine versus other anti-depressive agents for depressionCochrane Database Syst Rev201210CD00653323076926
   PubMed Web of Science ®Google Scholar
• ThaseMEEntsuahARRudolphRLRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitorsBr J Psychiatry200117823424111230034
   PubMed Web of Science ®Google Scholar
• BymasterFPLeeTCKnadlerMPDetkeMJIyengarSThe dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depressionCurr Pharm Des200511121475149315892657
   PubMed Web of Science ®Google Scholar
• SkljarevskiVZhangSDesaiahDPalaciosSMiazgowskiTPatrickKEfficacy and safety of duloxetine 60 mg once-daily in patients with chronic low back painJ Pain2010114S38
   Google Scholar
• FavaMMallinckrodtCHDetkeMJWatkinJGWohlreichMMThe effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?J Clin Psychiatry200465452153015119915
   PubMed Web of Science ®Google Scholar
• ChanHNFamJNgBYUse of antidepressants in the treatment of chronic painAnn Acad Med Singapore2009381197497919956820
   PubMed Web of Science ®Google Scholar
• JungACStaigerTSullivanMThe efficacy of selective serotonin reuptake inhibitors for the management of chronic painJ Gen Intern Med19971263843899192257
   PubMed Web of Science ®Google Scholar
• MowlaADastgheibSARazeghian JahromiLComparing the effects of sertraline with duloxetine for depression severity and symptoms: a double-blind, randomized controlled trialClin Drug Investig2016367539543
   PubMed Web of Science ®Google Scholar
• ChuangHYChangYHChengLYVenlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week studyChin J Physiol201457526527025241986
   PubMed Web of Science ®Google Scholar
• ZimmermanMMcglincheyJBPosternakMAFriedmanMAttiullahNBoerescuDHow should remission from depression be defined? The depressed patient’s perspectiveAm J Psychiatry2006163114815016390903
   PubMed Web of Science ®Google Scholar
• McKnightPEKashdanTBThe importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment researchClin Psychol Rev200929324325919269076
   PubMed Web of Science ®Google Scholar
• SolomonDALeonACEndicottJPsychosocial impairment and recurrence of major depressionCompr Psychiatry200445642343015526252
   PubMed Web of Science ®Google Scholar
• VittenglJRClarkLAJarrettRBDeterioration in psychosocial functioning predicts relapse/recurrence after cognitive therapy for depressionJ Affect Disord20091121–313514318539337
   PubMed Web of Science ®Google Scholar
• TrivediMHDunnerDLKornsteinSGPsychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended releaseJ Affect Disord2010126342042920510459
   PubMed Web of Science ®Google Scholar
• DueñasHBrnabicAJMLeeATreatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational periodInt J Psychiatry Clin Pract201115424225422121997
   PubMed Web of Science ®Google Scholar
• DueñasHLeeABrnabicAJFrequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or dulox-etine therapy: 8-week data from a 6-month observational studyInt J Psychiatry Clin Pract2011152809022121855
   PubMed Web of Science ®Google Scholar
• HongJNovickDMontgomeryWShould unexplained painful physical symptoms be considered within the spectrum of depressive symptoms?Clin Pract Epidemiol Ment Health201511113013925870649
   PubMedGoogle Scholar
• World Health OrganizationThe ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic GuidelinesGenevaWorld Health Organization19921267
   Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th editionWashington, DC2000
   Google Scholar
• GuyWECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication no. ADM 76-338)Rockville, MD, USAUS Department of Health, Education and Welfare
   Google Scholar
  Public Heal ServRockville, MD, USANational Institute of Mental Health1976534537
   Google Scholar
• McGahueyCAGelenbergAJLaukesCAThe Arizona Sexual Experience Scale (ASEX): reliability and validityJ Sex Marital Ther2000261254010693114
   PubMed Web of Science ®Google Scholar
• RushAJTrivediMHIbrahimHMThe 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depressionBiol Psychiatry200354557358312946886
   PubMed Web of Science ®Google Scholar
• KroenkeKSpitzerRLWilliamsJBPhysical symptoms in primary care: predictors of psychiatric disorders and functional impairmentArch Fam Med1994397747797987511
   PubMedGoogle Scholar
• SheehanDVThe Anxiety DiseaseScribner, New York, NY, USAGoogle Scholar1983206 Available from: http://books.google.ca/books/about/The_Anxiety_Disease.html?id=3RyxQgAACAAJ&pgis=1Accessed January 20, 2018
   Google Scholar
• RushAJBernsteinIHTrivediMHAn evaluation of the Quick Inventory Of Depressive Symptomatology and the Hamilton Rating Scale for depression: a sequenced treatment alternatives to relieve depression trial reportBiol Psychiatry200659649350116199008
   PubMed Web of Science ®Google Scholar
• SheehanDVHarnett-SheehanKSpannMEThompsonHFPrakashAAssessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scaleInt Clin Psychopharmacol2011262758321102344
   PubMed Web of Science ®Google Scholar
• BrooksRde CharroFRabinRThe measurement and valuation of health status using EQ-5D: a European perspectiveQual Life Res2005142571573
   Google Scholar
• ImaiKvan DykDACausal inference with general treatment regimes: generalizing the propensity scoreJ Am Stat Assoc200499467854866
   Web of Science ®Google Scholar
• FengPZhouXHZouQMFanMYLiXSGeneralized propensity score for estimating the average treatment effect of multiple treatmentsStat Med201231768169721351291
   PubMed Web of Science ®Google Scholar
• HaradaETokuokaHFujikoshiSIs duloxetine’s effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trialsPain2016157357758426882344
   PubMed Web of Science ®Google Scholar
• HongJNovickDMontgomeryWReal-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East AsiaAsia Pac Psychiatry201681515925808275
   PubMed Web of Science ®Google Scholar
• NovickDMontgomeryWHaroJMFunctioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in east AsiaNeuropsychiatr Dis Treat20161238339226966361
   PubMed Web of Science ®Google Scholar
• NovickDHongJMontgomeryWDueñasHGadoMHaroJMPredictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational studyNeuropsychiatr Dis Treat20151119720525653529
   PubMed Web of Science ®Google Scholar
• NelsonJCZhangQKelinKErikssonEDeberdtWBerkMBaseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressantsCurr Med Res Opin201329782783323581532
   PubMed Web of Science ®Google Scholar
• ChekroudAMGueorguievaRKrumholzHMTrivediMHKrystalJHMcCarthyGReevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approachJAMA Psychiatry201774437037828241180
   PubMed Web of Science ®Google Scholar
• ThaseMEPritchettYLOssannaMJSwindleRWXuJDetkeMJEfficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderJ Clin Psychopharmacol200727667267618004135
   PubMed Web of Science ®Google Scholar
• MartinezJMKatonWGreistJHA pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episodeInt Clin Psychopharmacol2012271172622027844
   PubMed Web of Science ®Google Scholar
• SheehanDVChokkaPRGrangerREWaltonRJRaskinJSagmanDClinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetineHum Psychopharmacol201126324225121681815
   PubMed Web of Science ®Google Scholar
• OakesTMMyersALMarangellLBAssessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocolHum Psychopharmacol2012271475622241678
   PubMed Web of Science ®Google Scholar
• IshakWWMirochaJJamesDQuality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-upActa Psychiatr Scand20151311516024954156
   PubMed Web of Science ®Google Scholar
• LangliebAMGuico-PabiaCJBeyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorderPrim Care Companion J Clin Psychiatry2010122PCC.09r0082620694113
   PubMedGoogle Scholar
• Development of the World Health Organization WHOQOL-BREF quality of life assessmentThe WHOQOL GroupPsychol Med19982835515589626712
   PubMed Web of Science ®Google Scholar
• AngstJSexual problems in healthy and depressed personsInt Clin Psychopharmacol199813Suppl 6S1S4
   PubMed Web of Science ®Google Scholar
• KugaATsujiTHayashiSAn observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysisNeuropsychiatr Dis Treat2017132105211428831259
   PubMed Web of Science ®Google Scholar
• ManciniMSheehanDVDemyttenaereKEvaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studiesInt Clin Psychopharmacol201227629830922954893
   PubMed Web of Science ®Google Scholar